Phase I open label trial of Abraxane (nab-paclitaxel) administered concurrently with radiotherapy in patients with locally advanced inoperable pancreatic adenocarcinoma.

This study tests a chemotherapy drug called Abraxane (nab-paclitaxel) given at the same time as radiotherapy in patients with locally advanced pancreatic cancer that cannot be surgically removed. Pancreatic cancer is very difficult to treat, and combining chemotherapy with radiation may work better than either alone. This early-phase study aims to find the highest safe dose of Abraxane that can be given alongside radiotherapy over 6 weeks. You may be eligible if: - You are 18 years of age or older - You have been diagnosed with adenocarcinoma of the pancreas that cannot be removed by surgery - Your cancer has not spread to distant parts of the body (no metastases) - You are in reasonably good health (ECOG performance status 0–2) - You have not had prior chemotherapy for this cancer - You are male or female You may NOT be eligible if: - Your cancer has already spread to other organs (metastatic disease) - You have previously received chemotherapy - You have another active cancer (except minor skin cancers) - You have serious heart problems or uncontrolled medical conditions - You are pregnant or breastfeeding - You have significant nerve damage (neuropathy) or hepatitis B Talk to your doctor about whether this trial might be right for you.